Further exploration of novel ADCs and other anti-HER2 drugs in early-stage HER2-Low breast cancer (ClinicalTrials.gov identifier: T-Dxd-NCT04553770; pyrotinib-NCT05165225) is underway, encouraged by the great success of improving the prognosis in a metastatic setting. This evidence concerns the gene ERBB2 and breast carcinoma.